



9° Meeting

Nuove Prospettive in Chimica Farmaceutica

XXIII National Meeting on Medicinal Chemistry

9th Young Medicinal Chemists Symposium

September 6-9, Salerno - Italy

Campus di Fisciano - Università degli Studi di Salerno



Abstract eBook



9° Meeting

Nuove Prospettive in Chimica Farmaceutica

***XXIII National Meeting on Medicinal Chemistry and
9th Young Medicinal Chemists Symposium
(XXIII NMMC – 9th NPCF)***

September 6-9, 2015

Fisciano, Salerno, Italy

Congress venue: Università degli Studi di Salerno (Fisciano)

TOPICS

- Anti-infective Agents
- Biophysics and Analytics in Drug Discovery
- Cancer
- Cardiovascular Diseases
- Central Nervous System
- Computer Aided Methods in Medicinal Chemistry
- Drug Delivery
- Drug Design
- Epigenetics
- Inflammation
- Metabolic Diseases
- Nutraceuticals and Nutrigenomics
- Pharmaceutical Analysis
- Pharmaceutical Biotechnologies
- Synthetic Methods and Strategies in Medicinal Chemistry



EFMC
European Federation
for Medicinal Chemistry

***XXIII National Meeting on Medicinal Chemistry
and 9th Young Medicinal Chemists Symposium
(XXIII NMMC – 9th NPCF)***

Organizing Institution

Medicinal Chemistry Division (*Divisione di Chimica Farmaceutica*) of the Italian Chemical Society

Organizing Committee

Ettore Novellino (President - Università di Napoli “Federico II”)

Rita Patrizia Aquino (Università di Salerno)

Cosimo Damiano Altomare (Università di Bari)

Alessia Bertamino (Università di Salerno)

Pietro Campiglia (Università di Salerno)

Sabrina Castellano (Università di Salerno)

Federico Corelli (Università di Siena)

Anna Maria D’Ursi (Università di Salerno)

Anna Ramunno (Università di Salerno)

Manuela Rodriguez (Università di Salerno)

Carmela Saturnino (Università di Salerno)

Gianluca Sbardella (Università di Salerno)

Scientific Committee

Girolamo Cirrincione (President – Università di Palermo)

Cosimo Damiano Altomare (Università di Bari)

Tiziano Bandiera (IIT)

Pietro Campiglia (Università di Salerno)

Federico Corelli (Università di Siena)

Sandro Cosconati (Gruppo Giovani SCI – Seconda Università degli studi di Napoli)

Gabriele Costantino (Università di Parma)

Federico Da Settimo (Università di Pisa)

Ersilia De Lorenzi (Università di Pavia)

Daniele Donati (Nerviano MS)

Ettore Novellino (Università di Napoli “Federico II”)

Maurizio Recanatini (Università di Bologna)

Gianluca Sbardella (Università di Salerno)

Welcome address

Dear Friends and Colleagues,

On behalf of the Organizing Committee, I am glad to welcome you all to the ***XXIII National Meeting on Medicinal Chemistry and 9th Young Medicinal Chemists Symposium***.

The meeting, organized by the Medicinal Chemistry Division (*Divisione di Chimica Farmaceutica*) of the Italian Chemical Society, will be held in the Campus of the University of Salerno (located in Fisciano - Salerno, Italy) - from September 6th to 9th, 2015.

The **XXIII NMMC** aims to provide a panel of scientists to interact and discuss the latest ideas, scientific breakthroughs and techniques. The meeting offers an exciting chance to debate future changes and to provide topical coverage of key disciplines, and to explore for cooperation and collaborations. Moreover, this edition of the meeting will be joint with the **9th Young Medicinal Chemists Symposium** “*Nuove Prospettive in Chimica Farmaceutica*” (**NPCF9**), directed to graduate, post-graduate, PhD students and young researchers operating in University or Industry.

The scientific programme includes

- three days of scientific presentations
- plenary lectures of eminent international scientists
- twenty parallel oral sessions with keynotes and short communications of distinguished scientists from Italy and abroad, poster sessions and an exhibition by companies working in the field
- attendance of over 300 delegates from Italy and other countries
(from Europe, America, Asia, both University and Industry).

I would like to thank all the speakers and participants for their contributions.

The Chairman
Ettore Novellino

SPONSORS

We acknowledge the support of the **XXIII NMMC and 9th NPCF** by the following institutions, companies and journals:

Official carrier for NMMC2015



ABSTRACT

Dihydroquinazoline and Triazinedione Derivatives as Prok1 and Prok2 receptor antagonists in HEK-293 transfected cells

Gianfranco Balboni,^a Cenzo Congiu,^a Alessandro Deplano,^a Monica Demurtas,^a Joon Seok Buyn,^b Joo Mi Sohn,^b Jae Yeol Lee,^b Oualid Sbail,^c Philippe Rondard,^c and Valentina Onnis^{a,*}

^a Department of Life and Environmental Sciences, Unit of Medicinal, Pharmacological and Nutraceutical Sciences, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy

^b Research Institute for Basic Sciences and Department of Chemistry, College of Sciences, Kyung Hee University, Seoul 130-701, Republic of Korea

^c CNRS UMR5203, INSERM U1191, Institut de Génomique Fonctionnelle, Montpellier, France

*vonnis@unica.it

Prokineticin were originally identified as potent agents mediating gut motility, but were later shown to promote angiogenesis in steroidogenic glands, heart and reproductive system. They also modulate neurogenesis, circadian rhythms, nociception, haematopoiesis as well as immune response.^[1] Prokineticin are thought to be associated with pathologies of the reproductive systems,^[2] myocardial infarction,^[3] and tumorigenesis.^[4,5] Consequently, antagonism of the prokineticins functions may have utility in the treatment of disorders or diseases including gastrointestinal motility, angiogenesis, haematopoiesis, diabetes and pain.

Here we report the identification and pharmacological characterization of a new prototype (KYS-05090) in comparison with our reference prokineticin receptor antagonist (PC-7),^[6,7] (Figure 1).




Figure 1. Prokineticin receptor antagonists

References

1. Negri, L.; Lattanzi, R.; Giannini, E.; Canestrelli, M.; Nicotra, A.; Melchiorri, P. Bv8/prokineticins and their receptors: a new pronociceptive system. *Int. Rev. Neurobiol.* **2009**, *85*, 145-157.
2. Xiao, L.; Zhang, C.; Li, X.; Gong, S.; Hu, R.; Balasubramanian, R.; Crowely, W.F. Jr; Hastings, M.H.; Zhou, Q-Y. Signaling Role of Prokineticin 2 on the Estrous Cycle of Female Mice. *PlosOne* **2014**, *9*, e98314.
3. Attramadal, H. Prokineticins and the heart: diverging actions elicited by signaling through prokineticin receptor-1 or -2. *Cardiovasc. Res.* **2009**, *81*, 3-4.
4. Monnier, J.; Samson, N. Cytokine properties of prokineticins. *FEBS J.* **2008**, *275*, 4014-4021.
5. Shojaei, F.; Wu, X.; Zhong, C.; Yu, L.; Liang, X. H.; Yao, J.; Blanchard D.; Bais, C.; Peale, F. V.; van Bruggen, N.; Ho, C.; Ross, J.; Tan, M.; Carano, R. A.; Meng, Y. G.; Ferrara, N. Bv8 regulates myeloid-cell-dependent tumor angiogenesis. *Nature* **2007**, *450*, 825-831.
6. Jang, S.J.; Choi, H.W.; Choi, D.L.; Cho, S.; Rim, H.K.; Choi, H.E.; Kim, K.S.; Huang, M.; Rhim, H.; Lee, K.T.; Lee J.Y. In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers. *Bioorg. Med. Chem Lett.* **2013**, *23*, 6656-6662.
7. Congiu, C.; Onnis, V.; Deplano, A.; Salvadori, S.; Marconi, V.; Maftei, D.; Negri, L.; Lattanzi, R.; Balboni, G. A new convenient synthetic method and preliminary pharmacological characterization of triazinediones as prokineticin receptor antagonists. *Eur. J. Med. Chem.* **2014**, *81*, 334-340.